Immunosuppressant drug spending tied to transplant care is projected to surge to $28.7 billion by 2029, even as clinical strategies keep shifting how organs are preserved, matched, and prioritized. From machine perfusion and desensitization protocols to allocation rules and coordinator workflows, the data reveal sharp tradeoffs that look very different depending on the organ. Here are the statistics behind those decisions and outcomes, including what they mean for survival, rejection risk, and the true cost of getting a transplant done.
Key Takeaways
- In the United States, 3% of kidney transplants used domino or advanced cross-donor arrangements in 2023 (OPTN/HRSA living donor advanced program reporting)
- The Eurotransplant region performed 9,000+ transplants in the most recently reported year (annual Eurotransplant activity reporting)
- In the United States, the 1-year survival rate after lung transplant was 80% (2018–2022 cohort reported in OPTN/HRSA outcomes materials)
- A 2020 systematic review found that in kidney transplantation, desensitization protocols can enable ABO-incompatible and HLA-incompatible transplants with acceptable short-term graft outcomes (meta-analytic pooled results)
- A 2021 JAMA study reported that kidney transplants from deceased donors preserved with machine perfusion had improved graft survival versus static cold storage for certain donor profiles (pooled effect reported)
- In a 2022 trial, proton pump inhibitors were associated with a reduced incidence of delayed gastric emptying-related complications after certain transplant-related procedures (randomized trial results)
- In 2023, North America accounted for 41% of the organ transplantation market (industry market study estimate)
- By 2029, the immunosuppressant drugs market is forecast to reach $28.7 billion (MarketsandMarkets forecast)
- The U.S. healthcare spending on immunosuppressive medications for transplant patients was estimated at $3.7 billion in 2022 (peer-reviewed cost analysis)
- In a payer perspective analysis, kidney transplant care costs were estimated at $100,000–$180,000 in the first year post-transplant (range reported by published economic evaluations)
- A 2021 cost-effectiveness analysis found that kidney transplantation dominated or was cost-effective versus dialysis at commonly used U.S. thresholds (economic model results)
- A 2023 study in NEJM reported that machine perfusion reduced delayed graft function in deceased donor kidney transplants by 16% relative (reported hazard/odds ratios)
- A 2020 randomized trial found that HLA-matched kidney transplants improved 5-year graft survival versus mismatched transplants (reported survival rates)
- A 2019 meta-analysis found that donor-specific antibody targeting strategies reduced antibody-mediated rejection risk by 30% (pooled risk ratio reduction)
- A 2021 BMJ study reported that consent legislation and donor conversation policies were associated with 10%–20% increases in donation rates (reported effect sizes across studies)
Recent research shows improved transplant outcomes from better compatibility strategies and machine perfusion.
Related reading
01 · Category
Utilization & Waiting2 stats
01
In the United States, 3% of kidney transplants used domino or advanced cross-donor arrangements in 2023 (OPTN/HRSA living donor advanced program reporting)https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/
02
The Eurotransplant region performed 9,000+ transplants in the most recently reported year (annual Eurotransplant activity reporting)https://www.eurotransplant.org/cms/index.php?page=annual-reports
Interpretation
Utilization & Waiting Interpretation
For the Utilization and Waiting angle, the United States used domino or advanced cross-donor arrangements for 3% of kidney transplants in 2023, showing that these strategies are still a relatively small share of access pathways while the Eurotransplant region reported 9,000+ transplants in its most recent year, reflecting active utilization at scale.
02 · Category
Outcomes & Survival1 stats
01
In the United States, the 1-year survival rate after lung transplant was 80% (2018–2022 cohort reported in OPTN/HRSA outcomes materials)https://optn.transplant.hrsa.gov/media/4282/optn_outcomes_2024_q1.pdf
Interpretation
Outcomes & Survival Interpretation
For Outcomes and Survival in the United States, lung transplant recipients had an 80% 1-year survival rate for the 2018–2022 cohort, indicating solid short term survival performance.
03 · Category
Immunosuppression & Compatibility6 stats
01
A 2020 systematic review found that in kidney transplantation, desensitization protocols can enable ABO-incompatible and HLA-incompatible transplants with acceptable short-term graft outcomes (meta-analytic pooled results)https://pubmed.ncbi.nlm.nih.gov/32027888/
02
A 2021 JAMA study reported that kidney transplants from deceased donors preserved with machine perfusion had improved graft survival versus static cold storage for certain donor profiles (pooled effect reported)https://pubmed.ncbi.nlm.nih.gov/34120066/
03
In a 2022 trial, proton pump inhibitors were associated with a reduced incidence of delayed gastric emptying-related complications after certain transplant-related procedures (randomized trial results)https://pubmed.ncbi.nlm.nih.gov/36196553/
04
In the United States, 32% of liver transplant recipients received MELD-based priority status at time of transplant (OPTN policy-based allocation reporting)https://optn.transplant.hrsa.gov/media/3642/optn_policies.pdf
05
A 2022 study reported that ABO-incompatible kidney transplants had comparable 1-year survival to compatible transplants after desensitization (reported pooled 1-year survival)https://pubmed.ncbi.nlm.nih.gov/35719631/
06
A 2020 meta-analysis found that increased HLA mismatch was associated with a 1.2x higher risk of graft loss (pooled risk ratio per mismatch)https://pubmed.ncbi.nlm.nih.gov/31936476/
Interpretation
Immunosuppression & Compatibility Interpretation
Across kidney transplantation and broader compatibility settings, the evidence shows that careful compatibility management can meaningfully improve outcomes, such as desensitization enabling ABO and HLA incompatible grafts with acceptable short term results and pooled 1 year survival comparable to compatible transplants, while every additional HLA mismatch increases graft loss risk by about 1.2 times.
04 · Category
Market Size2 stats
01
In 2023, North America accounted for 41% of the organ transplantation market (industry market study estimate)https://www.fortunebusinessinsights.com/organ-transplantation-market-103311
02
By 2029, the immunosuppressant drugs market is forecast to reach $28.7 billion (MarketsandMarkets forecast)https://www.marketsandmarkets.com/Market-Reports/immunosuppressant-drugs-market-199890295.html
Interpretation
Market Size Interpretation
For the market size outlook, North America represents 41% of the organ transplantation market in 2023, and by 2029 the immunosuppressant drugs market is projected to reach $28.7 billion, signaling sustained growth around key transplant-related spending.
More related reading
05 · Category
Cost Analysis7 stats
01
The U.S. healthcare spending on immunosuppressive medications for transplant patients was estimated at $3.7 billion in 2022 (peer-reviewed cost analysis)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902868/
02
In a payer perspective analysis, kidney transplant care costs were estimated at $100,000–$180,000 in the first year post-transplant (range reported by published economic evaluations)https://www.ncbi.nlm.nih.gov/books/NBK470080/
03
A 2021 cost-effectiveness analysis found that kidney transplantation dominated or was cost-effective versus dialysis at commonly used U.S. thresholds (economic model results)https://jamanetwork.com/journals/jama-health-forum/fullarticle/2779115
04
In a 2019 analysis, living donor kidney transplantation reduced total costs compared with deceased donor transplantation due to shorter waiting and complications (economic evaluation published results)https://pubmed.ncbi.nlm.nih.gov/30573307/
05
A 2020 systematic review reported that organ transplant procurement costs accounted for about 5%–10% of total transplant program costs (pooled estimate across studies)https://pubmed.ncbi.nlm.nih.gov/33016367/
06
A 2022 hospital cost study found that ICU costs comprised 30%–45% of total cost for liver transplant admissions (reported distribution in published cost accounting study)https://pubmed.ncbi.nlm.nih.gov/35622510/
07
A 2020 analysis found that machine perfusion increases upfront costs by about $1,500–$4,000 per kidney transplant but may reduce graft loss (economic model results)https://pubmed.ncbi.nlm.nih.gov/32618314/
Interpretation
Cost Analysis Interpretation
Across cost analyses, the overall transplant cost burden is shaped by high first year and procedure related expenses, with immunosuppressive spending reaching about $3.7 billion in 2022 and ICU care for liver transplants making up roughly 30% to 45% of admission costs, while specific drivers like living donor and machine perfusion can shift costs modestly such as $1,500 to $4,000 in added upfront spending per kidney for potentially lower graft loss.
06 · Category
Performance Metrics3 stats
01
A 2023 study in NEJM reported that machine perfusion reduced delayed graft function in deceased donor kidney transplants by 16% relative (reported hazard/odds ratios)https://pubmed.ncbi.nlm.nih.gov/37276604/
02
A 2020 randomized trial found that HLA-matched kidney transplants improved 5-year graft survival versus mismatched transplants (reported survival rates)https://pubmed.ncbi.nlm.nih.gov/32009663/
03
A 2019 meta-analysis found that donor-specific antibody targeting strategies reduced antibody-mediated rejection risk by 30% (pooled risk ratio reduction)https://pubmed.ncbi.nlm.nih.gov/30692062/
Interpretation
Performance Metrics Interpretation
Across key performance metrics, interventions appear to deliver clear outcome gains, with machine perfusion cutting delayed graft function by 16%, HLA matching boosting 5 year graft survival, and antibody targeting lowering antibody mediated rejection risk by 30%.
07 · Category
Industry Trends3 stats
01
A 2021 BMJ study reported that consent legislation and donor conversation policies were associated with 10%–20% increases in donation rates (reported effect sizes across studies)https://pubmed.ncbi.nlm.nih.gov/34481920/
02
A 2020 JAMA Network Open study found that transplant coordinators improve evaluation completion by about 25% (observational impact study)https://pubmed.ncbi.nlm.nih.gov/33084183/
03
In 2023, the FDA approved 1 new immunosuppressive therapy related to organ transplantation (FDA approvals count in relevant years)https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots
Interpretation
Industry Trends Interpretation
Industry trends in organ transplantation show clear momentum in enabling more donors and improving processes, with 2021 evidence linking consent legislation and donor conversation policies to 10% to 20% higher donation rates and a 2020 study finding that transplant coordinators boost evaluation completion by about 25%, alongside continued FDA activity with 1 new immunosuppressive therapy approved in 2023.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Organ Transplantation Statistics. Gitnux. https://gitnux.org/organ-transplantation-statistics
MLA
Stefan Wendt. "Organ Transplantation Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/organ-transplantation-statistics.
Chicago
Stefan Wendt. 2026. "Organ Transplantation Statistics." Gitnux. https://gitnux.org/organ-transplantation-statistics.
Sources & references
24 datasets cited across this report
+16 additional datasets cited (not shown individually)